324 related articles for article (PubMed ID: 26812886)
1. Tumor resistance to vascular disrupting agents: mechanisms, imaging, and solutions.
Liang W; Ni Y; Chen F
Oncotarget; 2016 Mar; 7(13):15444-59. PubMed ID: 26812886
[TBL] [Abstract][Full Text] [Related]
2. Vascular disrupting agents: a new class of drug in cancer therapy.
Gaya AM; Rustin GJ
Clin Oncol (R Coll Radiol); 2005 Jun; 17(4):277-90. PubMed ID: 15997924
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of tumor resistance to small-molecule vascular disrupting agents: treatment and rationale of combination therapy.
Wu XY; Ma W; Gurung K; Guo CH
J Formos Med Assoc; 2013 Mar; 112(3):115-24. PubMed ID: 23473523
[TBL] [Abstract][Full Text] [Related]
4. Pericyte-targeting prodrug overcomes tumor resistance to vascular disrupting agents.
Chen M; Lei X; Shi C; Huang M; Li X; Wu B; Li Z; Han W; Du B; Hu J; Nie Q; Mai W; Ma N; Xu N; Zhang X; Fan C; Hong A; Xia M; Luo L; Ma A; Li H; Yu Q; Chen H; Zhang D; Ye W
J Clin Invest; 2017 Oct; 127(10):3689-3701. PubMed ID: 28846068
[TBL] [Abstract][Full Text] [Related]
5. Combination of vascular disrupting agents and ionizing radiation.
Clémenson C; Chargari C; Deutsch E
Crit Rev Oncol Hematol; 2013 May; 86(2):143-60. PubMed ID: 23177097
[TBL] [Abstract][Full Text] [Related]
6. Drug insight: vascular disrupting agents and angiogenesis--novel approaches for drug delivery.
Cooney MM; van Heeckeren W; Bhakta S; Ortiz J; Remick SC
Nat Clin Pract Oncol; 2006 Dec; 3(12):682-92. PubMed ID: 17139319
[TBL] [Abstract][Full Text] [Related]
7. Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies.
Kanthou C; Tozer GM
Int J Exp Pathol; 2009 Jun; 90(3):284-94. PubMed ID: 19563611
[TBL] [Abstract][Full Text] [Related]
8. Vascular disrupting agents (VDAs) in anticancer therapy.
Daenen LG; Roodhart JM; Shaked Y; Voest EE
Curr Clin Pharmacol; 2010 Aug; 5(3):178-85. PubMed ID: 20406172
[TBL] [Abstract][Full Text] [Related]
9. The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents.
Siemann DW
Cancer Treat Rev; 2011 Feb; 37(1):63-74. PubMed ID: 20570444
[TBL] [Abstract][Full Text] [Related]
10. Antiangiogenic and vascular-disrupting agents in endometriosis: pitfalls and promises.
Van Langendonckt A; Donnez J; Defrère S; Dunselman GA; Groothuis PG
Mol Hum Reprod; 2008 May; 14(5):259-68. PubMed ID: 18430758
[TBL] [Abstract][Full Text] [Related]
11. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors.
Shaked Y; Ciarrocchi A; Franco M; Lee CR; Man S; Cheung AM; Hicklin DJ; Chaplin D; Foster FS; Benezra R; Kerbel RS
Science; 2006 Sep; 313(5794):1785-7. PubMed ID: 16990548
[TBL] [Abstract][Full Text] [Related]
12. Vascular Disrupting Agents in cancer treatment: Cardiovascular toxicity and implications for co-administration with other cancer chemotherapeutics.
Gill JH; Rockley KL; De Santis C; Mohamed AK
Pharmacol Ther; 2019 Oct; 202():18-31. PubMed ID: 31173840
[TBL] [Abstract][Full Text] [Related]
13. Vascular disrupting agents (VDA) in oncology: advancing towards new therapeutic paradigms in the clinic.
Spear MA; LoRusso P; Mita A; Mita M
Curr Drug Targets; 2011 Dec; 12(14):2009-15. PubMed ID: 21777190
[TBL] [Abstract][Full Text] [Related]
14. Vascular disrupting agents in cancer therapy.
Smolarczyk R; Czapla J; Jarosz-Biej M; Czerwinski K; Cichoń T
Eur J Pharmacol; 2021 Jan; 891():173692. PubMed ID: 33130277
[TBL] [Abstract][Full Text] [Related]
15. Tumour vascular disrupting agents: combating treatment resistance.
Tozer GM; Kanthou C; Lewis G; Prise VE; Vojnovic B; Hill SA
Br J Radiol; 2008 Oct; 81 Spec No 1():S12-20. PubMed ID: 18819993
[TBL] [Abstract][Full Text] [Related]
16. Pictorial Imaging-Histopathology Correlation in a Rabbit with Hepatic VX2 Tumor Treated by Transarterial Vascular Disrupting Agent Administration.
He J; Liu C; Li T; Liu Y; Wang S; Zhang J; Chen L; Wang C; Feng Y; Floris G; Wang Z; Zhang X; Zhao L; Li Y; Shao H; Ni Y
Int J Med Sci; 2020; 17(15):2269-2275. PubMed ID: 32922191
[TBL] [Abstract][Full Text] [Related]
17. Reversing resistance to vascular-disrupting agents by blocking late mobilization of circulating endothelial progenitor cells.
Taylor M; Billiot F; Marty V; Rouffiac V; Cohen P; Tournay E; Opolon P; Louache F; Vassal G; Laplace-Builhé C; Vielh P; Soria JC; Farace F
Cancer Discov; 2012 May; 2(5):434-49. PubMed ID: 22588881
[TBL] [Abstract][Full Text] [Related]
18. Vascular targeting therapy: potential benefit depends on tumor and host related effects.
Horsman MR; Bohn AB; Busk M
Exp Oncol; 2010 Sep; 32(3):143-8. PubMed ID: 21403608
[TBL] [Abstract][Full Text] [Related]
19. Current development status of small-molecule vascular disrupting agents.
Chaplin DJ; Horsman MR; Siemann DW
Curr Opin Investig Drugs; 2006 Jun; 7(6):522-8. PubMed ID: 16784022
[TBL] [Abstract][Full Text] [Related]
20. Antiangiogenesis and vascular disrupting agents in cancer: circumventing resistance and augmenting their therapeutic utility.
Close A
Future Med Chem; 2016; 8(4):443-62. PubMed ID: 26933926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
